scholarly journals Successful Intravenous Immunoglobulin Therapy in 3 Cases of Parvovirus B19–Associated Chronic Fatigue Syndrome

2003 ◽  
Vol 36 (9) ◽  
pp. e100-e106 ◽  
Author(s):  
J. R. Kerr ◽  
V. S. Cunniffe ◽  
P. Kelleher ◽  
R. M. Bernstein ◽  
I. N. Bruce
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Intravenous Immunoglobulin ◽  
Parvovirus B19 ◽  
Immunoglobulin Therapy ◽  
Chronic Fatigue ◽  
Intravenous Immunoglobulin Therapy ◽  
Fatigue Syndrome

Paradoxical response to intravenous immunoglobulin in a case of Parvovirus B19-associated chronic fatigue syndrome

2015 ◽  
Vol 62 ◽  
pp. 54-57 ◽  
Author(s):  
Luciano Attard ◽  
Francesca Bonvicini ◽  
Francesco Gelsomino ◽  
Roberto Manfredi ◽  
Alessandra Cascavilla ◽  
...  
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Intravenous Immunoglobulin ◽  
Parvovirus B19 ◽  
Chronic Fatigue ◽  
Paradoxical Response ◽  
Fatigue Syndrome

scholarly journals Acute Parvovirus B19 Infection Mimicking Chronic fatigue Syndrome

2003 ◽  
Vol 42 (9) ◽  
pp. 903-905 ◽  
Author(s):  
Sadaya MATANO ◽  
Hiroya KINOSHITA ◽  
Kiyoaki TANIGAWA ◽  
Shintaro TERAHATA ◽  
Tatsuho SUGIMOTO
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Parvovirus B19 ◽  
Chronic Fatigue ◽  
Fatigue Syndrome ◽  
Parvovirus B19 Infection

A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome

1990 ◽  
Vol 89 (5) ◽  
pp. 554-560 ◽  
Author(s):  
Phillip K. Peterson ◽  
Judy Shepard ◽  
Mark Macres ◽  
Carlos Schenck ◽  
John Crosson ◽  
...  
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin G ◽  
Controlled Trial ◽  
Chronic Fatigue ◽  
Fatigue Syndrome ◽  
Intravenous Immunoglobulin G

scholarly journals Back to the Future? Immunoglobulin Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Healthcare ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1546
Author(s):  
Helen Brownlie ◽  
Nigel Speight
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Subcutaneous Administration ◽  
Immunoglobulin Therapy ◽  
Chronic Fatigue ◽  
Myalgic Encephalomyelitis ◽  
Placebo Control ◽  
Fatigue Syndrome ◽  
Symptom Exacerbation ◽  
High Degree ◽  
The Impact

The findings of controlled trials on use of intravenous immunoglobulin G (IV IgG) to treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are generally viewed as representing mixed results. On detailed review, a clearer picture emerges, which suggests that the potential therapeutic value of this intervention has been underestimated. Our analysis is consistent with the propositions that: (1) IgG is highly effective for a proportion of patients with severe and well-characterised ME/CFS; (2) responders can be predicted with a high degree of accuracy based on markers of immune dysfunction. Rigorous steps were taken in the research trials to record adverse events, with transient symptom exacerbation commonly experienced in both intervention and placebo control groups, suggesting that this reflected the impact of participation on people with an illness characterised by post-exertional symptom exacerbation. Worsening of certain specific symptoms, notably headache, did occur more commonly with IgG and may have been concomitant to effective treatment, being associated with clinical improvement. The findings emerging from this review are supported by clinical observations relating to treatment of patients with severe and very severe ME/CFS, for whom intramuscular and subcutaneous administration provide alternative options. We conclude that: (1) there is a strong case for this area of research to be revived; (2) pending further research, clinicians would be justified in offering a course of IgG to selected ME/CFS patients at the more severe end of the spectrum. As the majority of trial participants had experienced an acute viral or viral-like onset, we further suggest that IgG treatment may be pertinent to the care of some patients who remain ill following infection with SARS-CoV-2 virus.

Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection

2008 ◽  
Vol 14 (5) ◽  
pp. 377-382 ◽  
Author(s):  
Eiichi Ogawa ◽  
Shigeru Otaguro ◽  
Masayuki Murata ◽  
Mosaburo Kainuma ◽  
Yasunori Sawayama ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Parvovirus B19 ◽  
Immunoglobulin Therapy ◽  
Human Parvovirus B19 ◽  
Intravenous Immunoglobulin Therapy ◽  
Severe Arthritis ◽  
Parvovirus B19 Infection

Chronic Fatigue Syndrome after Human Parvovirus B19 Infection without Persistent Viremia

Dermatology ◽  
2008 ◽  
Vol 216 (4) ◽  
pp. 341-346 ◽  
Author(s):  
Mariko Seishima ◽  
Yoko Mizutani ◽  
Yoshinao Shibuya ◽  
Chikako Arakawa
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Parvovirus B19 ◽  
Chronic Fatigue ◽  
Human Parvovirus B19 ◽  
Fatigue Syndrome ◽  
Persistent Viremia ◽  
Parvovirus B19 Infection

scholarly journals Chronic Parvovirus B19 Infection Resulting in Chronic Fatigue Syndrome: Case History and Review

1997 ◽  
Vol 24 (6) ◽  
pp. 1048-1051 ◽  
Author(s):  
S. Kim Jacobson ◽  
Jennifer S. Daly ◽  
Grace M. Thorne ◽  
Kenneth McIntosh
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Case History ◽  
Parvovirus B19 ◽  
Chronic Fatigue ◽  
Chronic Fatigue Syndrome Case ◽  
Fatigue Syndrome ◽  
Parvovirus B19 Infection
Sign in / Sign up

Export Citation Format

Share Document